Inclusion Criteria:~1. Male or female, age 18 to 80 years at the time of informed consent~2. Individuals who
are confirmed to be mutation positive for presenilin 1 (PSEN1), amyloid precursor protein (APP), or presenilin
2 (PSEN2) gene that is associated with DIAD~3. Clinical Dementia Rating - Sum of Boxes (CDR-SB) score 5 to 12
at Screening~4. Able to undergo magnetic resonance imaging (MRI), lumbar puncture (LP), PET, and complete all
study-related testing and evaluations~5. Has a study partner who in the investigator's judgment is able to
provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide
information at the study visits which require informant input for scale completion~
